JP Morgan Knock-Out REGN/ DE000JQ7KLW5 /
| 2024-05-23 10:39:20 AM | Chg.+0.01 | Bid11:04:12 AM | Ask11:04:12 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 2.60EUR | +0.39% | 2.62 Bid Size: 5,000 |
2.71 Ask Size: 5,000 |
Regeneron Pharmaceut... | 709.3717 - | 2078-12-31 | Call |
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-17
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-08
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
04-29
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
04-25
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
04-24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire
04-22
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire
04-07
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...
GlobeNewswire
04-01
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...
GlobeNewswire
03-13
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientif...
GlobeNewswire
03-11
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High C...
GlobeNewswire
03-08
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) a...
GlobeNewswire
02-23
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...
GlobeNewswire
02-21
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Re...
GlobeNewswire
02-16
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
GlobeNewswire
02-02
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
02-02
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire
01-30
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platf...
